Carregant...
Ocrelizumab zur Behandlung der Multiplen Sklerose
Ocrelizumab is a monoclonal antibody directed against the differentiation antigen CD20, which leads to an effective long-term depletion of lymphocytes, in particular B cells. Recently published phase 3 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclero...
Guardat en:
| Publicat a: | Nervenarzt |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Medizin
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7286209/ https://ncbi.nlm.nih.gov/pubmed/32524163 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00115-020-00937-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|